{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:26:04Z","timestamp":1765887964480},"reference-count":13,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1136\/thoraxjnl-2017-211416","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T12:55:22Z","timestamp":1518612922000},"page":"210-212","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma"],"prefix":"10.1136","volume":"73","clinical-trial-number":[{"clinical-trial-number":"nct02040272","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01907100","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02709512","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02054806","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03063450","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02991482","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02899299","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"isrctn04240319","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn12698107","registry":"10.18810\/isrctn"}],"author":[{"given":"Ian","family":"Woolhouse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick A","family":"Maskell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"2020050723432112000_73.3.210.1","unstructured":"National Lung Cancer Audit. Pleural Mesothelioma Report 2016. London, UK: Royal College of Physicians, 2016."},{"key":"2020050723432112000_73.3.210.2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.087619"},{"key":"2020050723432112000_73.3.210.3","doi-asserted-by":"crossref","unstructured":"Woolhouse I , Bishop L , Darlison L , et al . BTS Guideline for the investigation and management of malignant pleural mesothelioma. Thorax 2018.","DOI":"10.1136\/thoraxjnl-2017-211416"},{"key":"2020050723432112000_73.3.210.4","doi-asserted-by":"crossref","unstructured":"Woolhouse I , Bishop L , Darlison L , et al . BTS Guideline for the investigation and management of malignant pleural mesothelioma. BMJ Open Respiratory Research 2018.","DOI":"10.1136\/bmjresp-2017-000266"},{"key":"2020050723432112000_73.3.210.5","unstructured":"AGREE Advancing the science of practice guidelines. AGREE II. www.agreetrust.org\/resource-centre\/agree-ii\/"},{"key":"2020050723432112000_73.3.210.6","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205205"},{"key":"2020050723432112000_73.3.210.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1115050"},{"key":"2020050723432112000_73.3.210.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60418-9"},{"issue":"Suppl 1","key":"2020050723432112000_73.3.210.9","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0169-5002(16)30212-4","article-title":"195 A feasibility study comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma: the MARS 2 study","volume":"91","author":"Lim","year":"2016","journal-title":"Lung Cancer"},{"key":"2020050723432112000_73.3.210.10","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1200\/jco.2015.33.15_suppl.7500","article-title":"Bevacizumab 15 mg\/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in malignant pleural mesothelioma (MPM): results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial","volume":"33","author":"Zalcman","year":"2015","journal-title":"J Clin Oncol"},{"key":"2020050723432112000_73.3.210.11","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo controlled LUME-Meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J Clin Oncol"},{"key":"2020050723432112000_73.3.210.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30095-X"},{"key":"2020050723432112000_73.3.210.13","unstructured":"Mesothelioma UK. Clinical Trials. http:\/\/www.mesothelioma.uk.com\/information-and-support\/clinical-trials"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2017-211416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T06:05:53Z","timestamp":1601100353000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2017-211416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,2,14]]},"published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1136\/thoraxjnl-2017-211416"],"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2017-211416","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,14]]}}}